Jan 19, 2023 | News, Press Releases
Results demonstrate a biological correlation between reduction in PTSD severity and treatment with MDMA-assisted therapy in veterans and first responders Study sheds light on neurological mechanisms that drive MDMA-assisted therapy in PTSD SAN JOSE, Calif.,...Jan 5, 2023 | News, Press Releases
Results met study pre-specified primary and key secondary endpoints and will support new drug application submission expected in third quarter of 2023 No serious adverse events observed in the MDMA group If approved, MAPS PBC’s MDMA-assisted therapy could be the...Nov 17, 2022 | News, Press Releases
Top-line data expected in the first quarter of 2023 Data to be part of new drug application submission expected in third quarter of 2023 SAN JOSE, Calif., November 17, 2022—MAPS Public Benefit Corporation (“MAPS PBC”), a private company dedicated to the development...Oct 4, 2022 | News, Press Releases
The new chairman brings critical commercial expertise and pharmaceutical leadership needed during MAPS PBC’s growth phase MDMA-assisted therapy, a novel treatment for post-traumatic stress disorder (PTSD) with FDA breakthrough therapy designation, is on track for new... 
Jun 29, 2022 | News, Press Releases
The FDA lifted the clinical hold from a MAPS-sponsored Phase 2 study of MDMA-assisted group therapy for the treatment of posttraumatic stress disorder among veterans at the VA Portland Health Care System This essential proof-of-principle study tests safety and... 
Jun 27, 2022 | News, Press Releases
On PTSD Awareness Day, MAPS PBC announces plans to develop the New Drug Application for MDMA-assisted therapy in collaboration with MMS Holdings The second Phase 3 trial of the Breakthrough-Designated Therapy for PTSD will be completed in late 2022, with a targeted...